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STUDY OF HYPERTENSIVE PRESCRIBING
PRACTICES
Schulman KA', Mehta SS', Gersh Bj2, Schneider EO,
Wilcox C'
'Clinical Economics Research Unit, -Division of Cardiology,
31nstitute for Health Care Research and Policy, 'Division of
Nephrology and Hypertension at Georgetown University
Medical Center, Washington, DC, USA
Fifty million people in the US have hypertension. The
jNC-V guidelines provide treatment recommendations
for hypertension. These guidelines promote initiating
therapy with diuretics and beta blockers since these
agents have been shown to reduce hypertension-related
morbidity and mortality.
OBJECTIVES: To survey primary care physicians' anti-
hypertensive prescribing practices, their perceptions
about antihypertensive medication cost and safety and
the perceived impact of managed care.
METHODS: A direct mail survey was sent to a national
random sample of 500 office-based, primary care intern-
ists, family practitioners, and general practitioners.
RESULTS: Seventy-two percent of physicians reported
being aware of the jNC-V guidelines. Younger physicians
claimed to be more aware of and more likely to follow
jNC-V guidelines than older physicians. Only 25% of
physicians reported initiating treatment at systolic blood
pressures greater than 140 mm Hg as recommended by
the jNC-V guidelines. Diuretics were selected by 36% of
physicians, angiotensin-converting enzyme (ACE) inhibi-
tors by 35%, beta blockers by 16%, and calcium channel
blockers (CCBs) by 7% for initial antihypertensive treat-
ment. Up to 27% of physicians admitted not knowing the
cost of specific medications. Approximately half of physi-
cians reported that they and their patients were more
concerned about medication cost and safety today than
18 months ago. A greater number of younger physicians
than older physicians reported that managed care formu-
laries infringed upon their prescribing practices.
CONCLUSIONS: Antihypertensive prescribing patterns
are inconsistent with jNC-V guidelines. Actual practice
may deviate even more from these guidelines than re-
ported in this survey. Also, primary care physicians per-
ceive that managed care is increasingly affecting their pre-
scribing practices.
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MEDICAL AND ECONOMIC OUTCOMES IN
PATIENTS TREATED WITH DILTIAZEM OR
DIGOXIN FOR ATRIAL FIBRILLATION:
A DATABASE ANALYSIS
Windisch PA. Vlasses PH, Jankowski L
University HealthSystem Consortium, Oak Brook, IL, USA
This study compared the use and outcomes associated
with intravenous diltiazem and/or intravenous digoxin as
Abstracts
a primary therapy in patients admitted for treatment of
atrial fibrillation.
METHODS: A retrospective database analysis was con-
ducted with data from seven academic medical centers.
The use of intravenous diltiazem, digoxin, or both, in pa-
tients admitted for treatment of atrial fibrillation between
january 1993 and july 1996 was analyzed. SAS data sets
were created to combine financial records with clinical
files. The primary outcomes of interest measured were
the length of hospital stay (LOS), total hospital cost, hos-
pital mortality, and 30-day readmission rates.
RESULTS: A total of 107 patients was identified in the Uni-
versity Health System Consortium (UHC) clinical database
(CDB) with admissions for treatment of atrial fibrillation.
46, 41, and 20 patients received intravenous diltiazem,
digoxin, or both agents, respectively. Hospital mortality
rates were not different among patients. The most common
concomitant disease states included congestive heart failure
(n = 28) and hypertension (n = 9). The mean LOS was
4.11, 8.34, and 9.15 days for patients receiving diltiazem,
digoxin, or both agents, respectively. The mean total cost of
hospitalization was $4,890, $11,063 and $13,547 for pa-
tients receiving diltiazem, digoxin, or both agents, respec-
tively. More patients receiving both agents were readmitted
within 30 days (25%) as compared to patients receiving
only diltiazem (8%) or digoxin (22%).
CONCLUSION: Intravenous diltiazem was associated
with a decreased LOS, decreased total hospital costs, a
decreased 30-day readmission rate and no difference in
mortality in comparison with intravenous digoxin.
Therefore, intravenous diltiazem warrants further consid-
eration as a replacement for intravenous digoxin in the
cost-effective management of atrial fibrillation.
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THE IMPACT OF UNSTABLE ANGINA ON THE
USE OF MEDICAL RESOURCES IN ITALY
Maggioni AP. Schweiger C. Tavazzi L, on behalf of the
EARISA Investigators
ANMCO Research Center, Florence, Italy
Due to the recent changes in the strategies of treatment,
and the public health relevance of unstable angina (UA), it
is important to define epidemiology of interventions in or-
der to plan appropriate use of resources. The Italian Asso-
ciation of Hospital Cardiologists (ANMCO) planned to
conduct a registry on patients with acute coronary syn-
dromes (ACS).
METHODS: Data were collected at hospital discharge on
2,943 patients with ACS over 2 weeks (February 12-23,
1996) by 308 cardiological centers (81% of the existing
centers in Italy).
RESULTS: UA accounted for 1,420 cases (48%), while
AMI for 1,523 patients (52%). The length of stay of pa-
tients with UA was 9 ± 6 days; about half of them were
admitted to a CCU (length of stay 4 ± 3 days). Proce-
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dures used in the UA patients during hospital stay are re-
ported below:
ONE·YEAR CLINICAL AND ECONOMIC
OUTCOMES OF PRIMARY CORONARY
ANGIOPLASTY USING A NATIONAL
DATABASE
Akhras KS. Lowe LP. Arguelles LM
G. D. Searle & Co., Chicago, IL,USA
PCYI II
PREVALENCE AND COST OF HOSPITALIZATIONS
DUE TO ANGINA IN THE UNITED STATES
USING A NATIONAL DATABASE
Akhras KS, Zhao SZ
G. D. Searle & Co., Chicago, IL,USA
(p = 0.0001), diabetes for angina rehospitaliza~ion (p =
0.06), and diabetes (p = 0.05) and hypertension (p =
0.004) for repeat PTCA. Total charges per patient at one
year after primary PTCA were $35,257, and total charges
were strongly related to the presence of diabetes (p =
0.001) and CHF (p = 0.001). There was no association
with hypertension or hypercholesterolemia.
CONCLUSION: These findings show that the presence
of certain comorbid factors does influence clinical and
economic outcomes following PTCA.
This study describes the prevalence and cost of hospital-
izations due to angina in the United States.
METHODS: Using the 1992 Health Care Utilization
(HCUP) database, patients admitted with the principle di-
agnosis of angina (ICD-9 codes 411.1, 413.1, 413.9)
were identified. Results were analyzed based on demo-
graphic distribution, procedures performed, mean length
of stay (LOS), and total charges.
RESULTS: The overall prevalence of hospitalizations due
to angina was 2.6%. The highest angina hospitalization
rates were among patients between the ages of 55-75
years (5.6%), male (3.4%), and white (3.1 %). The most
common type of diagnosis was unstable angina (79%),
followed by stable angina (19.8%). More than half
(55%) of admissions were through the emergency room
(ER), and 7.3 % were routine admissions. The most com-
mon procedures were removal of coronary artery ob-
struction (ICD-9 code 36), followed by other operations
on heart and pericardium (ICD-9 code 37). The mean
LOS and total charges were 4.87 days and $12,134, re-
spectively. Mean LOS and total charges per admission
varied significantly according to admission source: 4.6,
5.0, 6.9 days and $9,130, $15,120, $24,090 for ER ad-
mission, routine admission, and others (e.g., hospital
transfer), respectively. Since HCUP represents a 20%
sample of total US hospitalizations, total annual charges
for hospitalizations due to angina are approximately $10
billion, and the majority of that ($8.7 billion) is due to
unstable angina.
CONCLUSION: Hospitalization due to unstable angina
is the major cost component of the total cost of hospital
care for angina in the United States.
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Type I Type II TypeIIl Type IV Total
(n.30) (n.859) (n.357) (n.374) (n.1420)
Hospital
Noninvasive procedures
(NIP) %
Holter
Exercise stress test
Echocardiogram
Echo-stress
Nuclear cardiology
Invasive procedures (IP) %
Coronary angiography 3 13 58 68 39
PTCA 1 7 34 11
CABS 0.5 1 7 2
Type I: no CCU, no Cath Lab, no cardiac surgery (CS);
Type II: CCU, no Cath Lab, no CS; Type III: CCU, Cath
Lab, no CS; Type IV: CCU, CathLab, CS.
CONCLUSION: In Italy the number of hospital admis-
sions due to UA is similar to that due to AMI. NIP were
performed more frequently in the hospitals without Cath-
Lab/CS. Hospitals' more than patients' characteristics in-
duced IP.
OBJECTIVE: To determine clinical and economic out-
comes of primary PTCA and assess the effects of comor-
bidities (congestive heart failure, diabetes, hypercholes-
terolemia, hypertension) on outcomes using a national
database.
METHODS: Data were obtained from Marketscana
Medstata, which contains claims data for 4-5 million
people. Patients with a hospital admission for PTCA
(CPT codes 92982, 92984) in 1992 and one year of fol-
low-up charge data were identified. A total of 2,663 pa-
tients with a single vessel and 331 with a multiple vessel
procedure were included. Patients who died or were miss-
ing prior to one-year follow-up were excluded (n = 653).
Total charges were calculated by summing charges for
the index procedure plus all inpatient and outpatient
charges incurred during the year following PTCA. Multi-
variate regression was used to assess effects of comorbidi-
ties on outcomes (adjusted for age and other factors).
RESULTS: Patients with single vessel versus multiple ves-
sel PTCA did not differ according to comorbid and other
characteristics, or most clinical or economic outcomes;
therefore combined data are presented. The frequency of
clinical outcomes in the year following PTCA was: rehos-
pitalization for angina-41 %, myocardial infarction (MI)-
33%, repeat PTCA-15%, coronary artery bypass graft-
ing-7%, and stroke-3%. Comorbidities related to clini-
cal outcomes were: congestive heart failure (CHF) for MI
